<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176472</url>
  </required_header>
  <id_info>
    <org_study_id>REGY-DN-201</org_study_id>
    <nct_id>NCT03176472</nct_id>
  </id_info>
  <brief_title>Ricolinostat in Patients With Diabetic Neuropathic Pain</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Diabetic Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenacy Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenacy Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, parallel group clinical study of up to 450 patients
      designed to evaluate the safety and efficacy of ricolinostat for Diabetic Neuropathic Pain
      (DNP).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Intensity (NRS)</measure>
    <time_frame>Baseline week [Day-7 to Day 1] compared to Final week [Day 22 to Day 28]</time_frame>
    <description>Difference between mean average pain intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory Questionnaire - Short Form (BPI-SF) pain score</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Change in mean BPI-SF pain intensity and interference score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy Total Symptom Score - 6 (NTSS-6)</measure>
    <time_frame>Day 1 to Day 28</time_frame>
    <description>Change in neuropathy symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Diabetic Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>ricolinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ricolinostat</intervention_name>
    <description>120 mg per dose in 12 mL liquid formulation</description>
    <arm_group_label>ricolinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>12 mL liquid formulation placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or Type 2 diabetes with optimized and stable glycemic control during the 3
             months prior to Screening

          -  Painful distal symmetric sensorimotor polyneuropathy ≥6 months

          -  Douleur Neuropathique 4 (DN4) score of ≥4

          -  Use and failure of at least 2 other treatments for neuropathic pain

          -  Satisfactory diary data during the 7-day Pain Observation period determined by an
             algorithm that includes diary compliance, overall level of pain and day-to-day
             variability in pain

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Body Mass Index (BMI) &gt;40 kg/m2

          -  Suicidal ideation/behavior as measured by the Columbia-Suicide Severity Rating Scale
             (C-SSRS)

          -  Radiculopathy or other neuropathic conditions, including chemotherapy-induced
             neuropathy

          -  Other chronic pain condition(s) that could affect compliance with pain medication
             restrictions or confound pain assessments

          -  Known history of opioid abuse or opioid dependence in the past 5 years, or opioid use
             at a dose of ≥30 morphine milligram equivalents (MME) on 3 or more days a week during
             the month prior to Screening

          -  Chronic use of over-the-counter capsaicin on extremities within 3 months of Screening
             and/or prescription Qutenza use within 6 months of Screening

          -  Corrected QT interval at Screening using QTcF of ≥480 msec in the presence of a QRS
             &gt;120 msec

          -  Any of the following hematology abnormalities at Screening;

          -  Hemoglobin &lt;11.5 g/dL (female) or &lt;13 g/dL (male)

          -  Complete blood count outside the normal reference range

          -  Creatinine &gt;1.5 mg/dL or a calculated creatinine clearance of &lt;60 mL/min

          -  Serum bilirubin values &gt;2.0 mg/dL (&gt;3.0 mg/dL for hereditary benign
             hyperbilirubinemia) and serum alanine aminotransferase (ALT) and/or aspartate
             aminotransferase (AST) values &gt;1.5 x the upper limit of normal

          -  HIV positive and/or active hepatitis virus (A, B, or C) infection

          -  Current or previous (≤1 month of Screening) enrollment in a clinical trial involving
             treatment with an investigational product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Neuropathic Pain</keyword>
  <keyword>Neuropathic Pain</keyword>
  <keyword>HDAC6</keyword>
  <keyword>ricolinostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

